AGER and atherosclerosis: Preclinical evidence suggests that calprotectin may not only reflect neutrophilic inflammation but may also be directly involved in atherosclerosis through activating the vascular endothelium, actively recruiting neutrophils and inflammatory monocytes, and interacting with the receptor for advanced glycation end-products (RAGE), triggering inflammatory and thrombotic responses and further aggravating atherosclerosis [36,37,38].